Sarepta exchanges $700M of 1.25% notes due 2027 for new 4.875% notes due 2030, stock, and cash

Sarepta Therapeutics, Inc.

Exchanged ~$700M existing 1.25% convertible notes for $602M new 4.875% notes due 2030, $110M stock, and ~$123.3M cash.
New notes conversion price ~$60/share, representing a 191.5% premium over the $20.58 Aug 20 closing price.
Private placement of $20M common stock to J. Wood Capital Advisors at price with floor of $14.41/share.
Up to 835,765 fee shares may be issued to J. Wood Capital Advisors for advisory services.
Exchange expected to close Aug 28, 2025, subject to customary closing conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.